Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005141/en/
The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product and clinical testing capabilities all under one organization — extending the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceutics®. By cutting through silos and integrating a range of capabilities, outsourced development programs can be further simplified and accelerated, consistent with Quotient’s belief that molecules need to become cures, fast.
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.”
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018. Mark Bryant, BGF, said, “It has been a privilege to support the expansion of Arcinova’s world-leading CDMO facility at such a critical part of its growth journey. We wish the team all the best as it moves to the next stage with Quotient Sciences.”
RBC Capital Markets acted as exclusive financial advisor to Quotient Sciences. PwC provided financial and tax due diligence services and Latham & Watkins provided legal counsel. BGF received legal counsel from Weightmans. KPMG served as corporate finance adviser for Arcinova, and Womble Bond Dickinson provided legal counsel.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.
Arcinova is a multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life changing medicines. The company, with decades of experience, combines agility with flexibility to provide an innovative approach to the development and manufacture of pharmaceutical products. Arcinova’s ambition is to save our clients valuable time, enabling them to rapidly bring life-changing medicines to market.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Second Quarter 20215.5.2021 22:15:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.77 per share of its common stock, payable on July 6, 2021 to shareholders of record as of June 25, 2021. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20210505006076/en/Contact information Michael DeVeau Chief Investor Relations & Communications Officer 212.708.7164 Mich
Zynga Announces First Quarter 2021 Financial Results5.5.2021 22:05:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA) today released financial results for its first quarter ended March 31, 2021 by posting management’s Q1 2021 Quarterly Earnings Letter to its Investor Relations website. Please see the attached Quarterly Earnings Letter or visit http://investor.zynga.com/financial-information/quarterly-results to access the letter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005238/en/ “We are off to an excellent start in 2021 with record Q1 results driven by breakout performances from our live services, new games and hyper-casual portfolio,” said Frank Gibeau, Chief Executive Officer at Zynga. “Today, we announced our intent to acquire Chartboost, a leading advertising and monetization platform. This transformational acquisition will combine Zynga’s high-quality games portfolio and first-party data with Chartboost’s proven advertising and monetization platform to create a new level of audience scale and mea
Zynga Enters Agreement to Acquire Chartboost5.5.2021 22:05:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Chartboost, a leading mobile programmatic advertising and monetization platform. Along with its talented team, Chartboost brings a global audience of more than 700 million monthly users and more than 90 billion monthly advertising auctions. Together, Zynga and Chartboost possess all the elements of a complete, next generation platform: high-quality content, direct player relationships, massive reach and full-stack advertising technology that can be applied across Zynga’s game portfolio and Chartboost’s advertising partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005033/en/ Zynga Enters Agreement to Acquire Chartboost Chartboost is a unified advertising platform that includes a Demand Side Platform (DSP) as well as Supply Side Platform (SSP) and mediation capabilities del
Altasciences Acquires Calvert Laboratories5.5.2021 18:59:00 CEST | Press release
Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories, a preclinical CRO located on the U.S.A.’s East Coast. This acquisition will complement Altasciences’ current preclinical West Coast operations, located just north of Seattle, WA. For more than 40 years, Calvert Laboratories has been working with clients to help develop the next generation of therapeutics aimed at extending and improving human life; in line with Altasciences’ focus on getting better drugs to the people who need them faster. “This acquisition will increase small molecule expertise as well as add efficacy pharmacology, ophthalmology, and carcinogenicity study capabilities, to Altasciences’ current preclinical offering. Furthermore, it expands Altasciences’ presence on the East Coast, and the site is conveniently located in close p
RMS Global Catastrophe Model Leader Launches First Climate Change Models, Enabling New Risk Insights5.5.2021 17:14:00 CEST | Press release
RMS, the world’s leading catastrophe risk modeling and solutions company, revealed that according to its new Climate Change Models, and based on today’s exposures, insured average annual losses (AAL) from North Atlantic Hurricane wind could increase by as much as 24 percent by 2050*, and European Flood risk AAL could increase by up to 59 percent by 2050**, based on no mitigating factors taken. The new RMS Climate Change Models combine the RMS financial impact modeling framework with the best climate science consensus, including from the Intergovernmental Panel on Climate Change (IPCC). Generally available in June 2021, these models provide the most comprehensive climate change insights for North Atlantic Hurricane, Europe Inland Flood, and Europe Windstorm. Each model quantifies and differentiates the impacts of acute physical risk due to variable potential climate change scenarios (known as Representative Concentration Pathways or RCPs), different time horizons, and within specific re
Nel ASA: Receives Purchase Order for 2 MW PEM Electrolyser5.5.2021 16:46:00 CEST | Press release
Nel Hydrogen Electrolyser, a division of Nel ASA (Nel, OSE:NEL), received a purchase order for a 2 MW, fully containerized MC400 electrolyser from H2 Energy. "This is a new milestone achieved in the development of a commercial green hydrogen infrastructure, clearly showing that hydrogen for heavy duty vehicles is a reality today. We are proud that our compact PEM containerized solution has been selected for this second site to supply the refueling stations network," says Raymond Schmid, VP Sales and Marketing EMEA, Nel Hydrogen Electrolyser. The 2 MW PEM electrolyser is the second system to be delivered as part of the green hydrogen infrastructure network that is currently supplying hydrogen to the first 46 Hyundai trucks already operating in Switzerland and aiming to reach a fleet of 1,600 by 2025. The system will be filling 350 barg trailers directly at site to dispatch the hydrogen to the Hydrospider network in Switzerland. H2 Energy is working together with various partners to esta
Sevan Multi-Site Solutions Celebrates 10 Years5.5.2021 15:00:00 CEST | Press release
Sevan Multi-Site Solutions, Inc. (Sevan)—a global leader in innovative design, program management, construction services and data analytics—is excited to celebrate its 10th anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005438/en/ Sevan Multi-Site Solutions celebrates its 10th Anniversary. (Graphic: Business Wire) For a decade, Sevan has committed to providing multi-site solutions for dozens of clients along entire project life cycles. Sevan stays true to the values and core principles it was founded on: Integrity, Respect, Teamwork, Excellence and Charity. Since its inception, Sevan’s entrepreneurial spirit has been accompanied by a culture that is innovative, respectful, inclusive and progressive. “What a joy it has been to work with marvelous people over the last decade while we grew our business,” Jim Evans, President and CEO said. “Thanks so much to our clients, business partners and Sevan team member
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom